Product Profiles: Prostate Cancer – Recent approvals create competitive environment for new market entrants

Introduction

Androgen deprivation therapies (ADTs) are the main treatment type for hormone-sensitive prostate cancer. As the disease is hormonally fuelled, chemical castration provides adequate disease control for a number of years. The greatest level of unmet need exists for castrate-resistant patients. There are currently nine drugs in development for this disease stage.

Features and benefits

• In-depth analysis of the prostate cancer pipeline – drug profiles, product positioning and clinical and commercial attractiveness of pipeline drugs.
  
• Overview of key events leading to Taxotere (docetaxel; Sanofi) becoming the standard of care for metastatic castrate-resistant prostate cancer.
  
• Discussion of key marketed drugs for prostate cancer and attributes differentiating them.
  
• Review of current therapies and their ability to fulfill unmet needs compared to the current standard of care, Taxotere (docetaxel; Sanofi).

Highlights

Developers will face strong competition from recently approved therapies. These newly approved therapies must now be sequenced in order for patients to receive the most appropriate treatment.

Toxicity is a major consideration for older patients with advanced stages of disease. Choice of therapy must consider toxicity rates in addition to other patient specifics. The older age of the prostate cancer population (with an average diagnosis age of 68) limits the number of treatments prostate cancer patients are able to tolerate.

Any potential new therapies for metastatic castrate-resistant prostate cancer must show clinical benefits equal to or superior than the three recently approved therapies and the current standard of care, Taxotere (docetaxel; Sanofi) to maximize commercial success and penetrate the prostate cancer market.

Your key questions answered

• Understand how the dynamics of prostate cancer treatment are changing as a result of emerging therapies.
  
• Analyze targets for pipeline drugs in development, assessing how these may be achieved through well designed clinical trialing.
  
• Compare and contextualize pipeline drugs through reviewing clinical data and comparing to drugs already on the market.